Get the Stockscreener App
4.95
0.00%
0.00
Exicure Inc stock is traded at $4.95, with a volume of 83,191.
It is up +0.00% in the last 24 hours and up +27.74% over the past month.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.
See More
Previous Close:
$4.95
Open:
$5.19
24h Volume:
83,191
Relative Volume:
1.65
Market Cap:
$32.09M
Revenue:
$500.00K
Net Income/Loss:
$-7.88M
P/E Ratio:
-2.9221
EPS:
-1.694
Net Cash Flow:
$-5.49M
1W Performance:
+15.93%
1M Performance:
+27.74%
6M Performance:
-57.25%
1Y Performance:
+84.70%
1-Day Range:
$5.01
$5.56
1-Week Range:
$4.23
$5.88
52-Week Range:
$2.15
$36.00
Exicure Inc Stock (XCUR) Company Profile
Name
Exicure Inc
Sector
Industry
Phone
847-673-1707
Address
2430 N. HALSTED ST., CHICAGO, IL
Compare XCUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
4.70 | 5.31B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
19.91 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.55 | 113.25M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.2028 | 445.05M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.05 | 0 | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-18-20 | Initiated | BMO Capital Markets | Outperform |
| Nov-20-19 | Initiated | Guggenheim | Buy |
Exicure Inc Stock (XCUR) Latest News
What margin trends mean for Exicure Inc. stockWeekly Market Report & Free High Return Stock Watch Alerts - newser.com
Volume spikes in Exicure Inc. stock – what they mean2025 EndofYear Setup & Fast Entry High Yield Tips - newser.com
Building trade automation scripts for Exicure Inc.July 2025 Closing Moves & Safe Capital Growth Stock Tips - newser.com
Will Exicure Inc. bounce back from current supportWeekly Profit Recap & Daily Oversold Stock Bounce Ideas - newser.com
Exicure’s (XCUR) “Sell (D-)” Rating Reiterated at Weiss Ratings - Defense World
Can Exicure Inc. (2H0) stock attract analyst upgradesSwing Trade & Expert Verified Stock Movement Alerts - newser.com
Should you hold or exit Exicure Inc. now2025 Volume Leaders & Advanced Swing Trade Entry Alerts - newser.com
Is Exicure Inc. (2H0) stock a safe buy pre earningsJuly 2025 Catalysts & Risk Controlled Stock Pick Alerts - newser.com
How analysts revise price targets for Exicure Inc. (2H0) stockJuly 2025 Final Week & Risk Managed Investment Signals - newser.com
Will Exicure Inc. stock reach Wall Street targets2025 Dividend Review & Verified Entry Point Detection - newser.com
Chart overlay techniques for tracking Exicure Inc.2025 Bull vs Bear & AI Forecasted Stock Moves - newser.com
Exicure’s burixafor nears phase 2 data readout in multiple myeloma By Investing.com - Investing.com Nigeria
Exicure Highlights Recent Achievements and Near-Term Strategic Priorities - MarketScreener
Will breakout in Exicure Inc. lead to full recoveryPortfolio Update Summary & AI Based Buy and Sell Signals - newser.com
Exicure (XCUR) Progresses with Promising Results in Phase 2 Buri - GuruFocus
Exicure’s burixafor nears phase 2 data readout in multiple myeloma - Investing.com
Exicure Inc 2H0 Stock Analysis and ForecastTake Profit Strategies & Free Tremendous Portfolio Expansion - earlytimes.in
Exicure Reports Progress in Burixafor (GPC-100) Phase 2 Trial for Multiple Myeloma and Plans Expansion into Sickle Cell Disease and AML with New Leadership Appointments - Quiver Quantitative
Burixafor Phase 2 shows promising interim mobilization results; topline readout due in - Stock Titan
Is Exicure Inc. (2H0) stock a defensive play amid uncertaintyMarket Risk Summary & Verified Swing Trading Watchlist - newser.com
Can technical indicators confirm Exicure Inc.’s reversalWeekly Investment Recap & Fast Exit and Entry Strategy Plans - newser.com
Using flow based indicators on Exicure Inc.July 2025 Opening Moves & Fast Entry and Exit Trade Plans - newser.com
Will Exicure Inc. (2H0) stock benefit from sector leadershipEntry Point & Stock Market Timing Techniques - newser.com
Why Exicure Inc. (2H0) stock appeals to dividend investorsWeekly Investment Summary & Daily Volume Surge Trade Alerts - newser.com
Is Exicure Inc. (2H0) stock a buy before earnings resultsWeekly Trade Summary & Real-Time Buy Signal Notifications - newser.com
Risk vs reward if holding onto Exicure Inc.Weekly Market Summary & Reliable Intraday Trade Alerts - newser.com
Is Exicure Inc. (2H0) stock a fit for income portfoliosMarket Activity Recap & Community Verified Watchlist Alerts - newser.com
Developing predictive dashboards with Exicure Inc. dataEarnings Beat & Technical Entry and Exit Alerts - newser.com
Is Exicure Inc a good long term investmentBullish Engulfing Patterns & See Risk Factors Before Making Any Move - earlytimes.in
Exicure Inc Stock (XCUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):